Shanghai Ark Biopharmaceutical Co., Ltd.
PrivateLast Round
Series D
Jul 14, 2022
Est. Valuation
$694.8M
Total Funding Raised
$146.3M
Company Overview
Shanghai Ark Biopharmaceutical Co., Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series D round in July 2022.
Shanghai Ark Biopharmaceutical Co., Ltd. is a biopharmaceutical company that discovers and develops therapeutics for unmet medical needs in respiratory and pediatric diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Hardware Sales, Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Ark Biopharmaceutical Co., Ltd. Comparables
Compare Shanghai Ark Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enanta Pharmaceuticals | 77% | |
| Pfizer | 77% | |
| Sanofi | 71% |
For institutional investors. Book with your work email.
Shanghai Ark Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 14, 2022 | ||||
| Series C | Jan 22, 2021 | ||||
| Series A Extension | Feb 6, 2017 | ||||
| Series A | Apr 9, 2015 | ||||
| Angel | Feb 1, 2014 |
For institutional investors. Book with your work email.
Shanghai Ark Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriental Fortune Capital | Series C |
| Loyal Valley Capital | Series D |
| Oriza Holdings | Series C, Series D |
| Hillhouse Investment | Series C |
| Daoyuan Capital | Series C |
| DT Capital Partners | Series C |
| Jiangsu Ruihua Investment Holding Group | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 268% MoM.
- Jan 20, 2026
Monthly visitors increased 189% MoM, reaching 503.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 13, 2026
On Aug 13th '26, Ark Biosciences plans to advance AK0406's clinical development in China after approval of its IND, while continuing follow-up in Australia for the ongoing phase I study of the long-acting antiviral Fc conjugate candidate for influenza prophylaxis.
- partners_withAug 13, 2026
Ark Biosciences partners with Scripps Research Translational Institute.
- is_developingAug 13, 2026
Ark Biosciences develops antiviral drug-fc conjugate (AFC) candidate AK0406 for influenza prophylaxis, receives China IND approval on Aug 12th '26, and advances the candidate into clinical development in China while its Australian Phase I trial enters follow-up.
- partners_withAug 13, 2026
Ark Biosciences establishes a strategic partnership with Qilu Pharma Group for drug discovery and development.
- partners_withAug 13, 2026
Ark Biosciences maintains a strategic partnership with Genentech, Inc. for drug discovery and development.
For institutional investors. Book with your work email.
Shanghai Ark Biopharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai Ark Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai Ark Biopharmaceutical Co., Ltd. a public or private company?
Shanghai Ark Biopharmaceutical Co., Ltd. is a private company.
What is the current stock price of Shanghai Ark Biopharmaceutical Co., Ltd.?
Shanghai Ark Biopharmaceutical Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Shanghai Ark Biopharmaceutical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai Ark Biopharmaceutical Co., Ltd. worth (valuation)?
Shanghai Ark Biopharmaceutical Co., Ltd.'s valuation is estimated at $694.8M based on funding round data.
Can I buy Shanghai Ark Biopharmaceutical Co., Ltd. stock?
Shanghai Ark Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai Ark Biopharmaceutical Co., Ltd.'s last funding round?
Shanghai Ark Biopharmaceutical Co., Ltd.'s most recent funding round was Series D on July 14, 2022.
Who are the main investors in Shanghai Ark Biopharmaceutical Co., Ltd.?
Key investors in Shanghai Ark Biopharmaceutical Co., Ltd. include Loyal Valley Capital, Hillhouse Investment, Qiming Venture Partners, Decheng Capital, TPG.
Will Shanghai Ark Biopharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai Ark Biopharmaceutical Co., Ltd..
How can I track Shanghai Ark Biopharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai Ark Biopharmaceutical Co., Ltd.'s shares on secondary markets.